|
Case Report
Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
Myung-Hee Kang, Ji-Hyun Ju, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon, Ho-Cheol Kim, Gyeong-Won Lee
Korean J Intern Med. 2010;25(4):447-449. Published online November 27, 2010
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of breath and a persistent dry cough. A chest X-ray and computed tomography showed ..
|
|
|
Original Article
Severe Pulmonary Adverse Effects in Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Regimen Plus Rituximab
Kyu-Hyoung Lim, Ho-Il Yoon, Young Ae Kang, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jae Ho Lee, Choon-Taek Lee, Jong Seok Lee
Korean J Intern Med. 2010;25(1):86-92. Published online February 26, 2010
Background/AimsThe aim of our study was to determine the incidence and clinical features of severe pulmonary complications in patients receiving cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab plus CHOP (R-CHOP) as the initial treatment for lymph..
|
|
|
Case Report
Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy
Yuna Lee, Sun Young Kyung, Soo Jin Choi, Soo-Mee Bang, Seong Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(3):183-186. Published online September 30, 2006
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is..
|
|
|
